Share Email Print
cover

Proceedings Paper

Application of fluorescent tracer agent technology to point-of-care gastrointestinal permeability measurement
Author(s): Richard B. Dorshow; Jeng-Jong Shieh; Thomas E. Rogers; Carla Hall-Moore; Nurmohammad Shaikh; Michael Talcott; Phillip I. Tarr
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Gut dysfunction, often accompanied by increased mucosal permeability to gut contents, frequently accompanies a variety of human intestinal inflammatory conditions. These disorders include inflammatory bowel diseases (e.g., Crohn’s Disease) and environmental enteropathy and enteric dysfunction, a condition strongly associated with childhood malnutrition and stunting in resource poor areas of the world. The most widely used diagnostic assay for gastrointestinal permeability is the lactulose to mannitol ratio (L:M) measurement. These sugars are administered orally, differentially absorbed by the gut, and then cleared from the body by glomerular filtration in the kidney. The amount of each sugar excreted in the urine is measured. The larger sugar, lactulose, is minimally absorbed through a healthy gut. The smaller sugar, mannitol, in contrast, is readily absorbed through both a healthy and injured gut. Thus a higher ratio of lactulose to mannitol reflects increased intestinal permeability. However, several issues prevent widespread use of the L:M ratio in clinical practice. Urine needs to be collected over time intervals of several hours, the specimen then needs to be transported to an analytical laboratory, and sophisticated equipment is required to measure the concentration of each sugar in the urine. In this presentation we show that fluorescent tracer agents with molecular weights similar to those of the sugars, selected from our portfolio of biocompatible renally cleared fluorophores, mimic the L:M ratio test for gut permeability. This fluorescent tracer agent detection technology can be used to overcome the limitations of the L:M assay, and is amenable to point-of-care clinical use.

Paper Details

Date Published: 22 April 2016
PDF: 4 pages
Proc. SPIE 9723, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications VIII, 97230A (22 April 2016); doi: 10.1117/12.2211790
Show Author Affiliations
Richard B. Dorshow, MediBeacon, LLC (United States)
Jeng-Jong Shieh, MediBeacon, LLC (United States)
Thomas E. Rogers, MediBeacon, LLC (United States)
Carla Hall-Moore, Washington Univ. School of Medicine in St. Louis (United States)
Nurmohammad Shaikh, Washington Univ. School of Medicine in St. Louis (United States)
Michael Talcott, Washington Univ. School of Medicine in St. Louis (United States)
Phillip I. Tarr, Washington Univ. School of Medicine in St. Louis (United States)


Published in SPIE Proceedings Vol. 9723:
Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications VIII
Samuel Achilefu; Ramesh Raghavachari, Editor(s)

© SPIE. Terms of Use
Back to Top